Malignant Mesothelioma
Alfacell updates progress on development of Onconase in cancer
Published in Cancer Weekly, September 26th, 2006
This pivotal trial is evaluating the effectiveness of Onconase plus doxorubicin in improving the survival of patients with unresectable malignant mesothelioma (UMM) over doxorubicin alone.
The company's CEO and chairman of the board of directors, Kuslima Shogen, commented, "As a result of our recently completed financing we are in a strong position to further accelerate our clinical and regulatory strategy for Onconase. To date, we have accrued more...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
Source: Cancer Weekly (2006-09-26)
More Articles from Cancer Weekly
- Barrett Esophagus
Cancer in Barrett esophagus detected by elastic scattering spectroscopy - Cancer Therapy
Small molecule integrin alpha(V)beta(3) antagonists proposed as novel anticancer agents - Diagnostics
Negative screening colonoscopy need not be repeated - Acute Myeloid Leukemia
Leukemia linked to expression of B cell-specific activator protein - Adrenal Cancer
Adrenal malignancy management can include laparoscopic adrenalectomy as an option - Amphotericin B Toxicity
Amphotericin B-related nephrotoxicity increases hospital stay in immunocompromised patients - More from this issue of Cancer Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
